G. Hogeland

A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

H. Kantarjian, G. Garcia-Manero, E. Jabbour, 2014, Clinical Cancer Research.

Lopinavir/ritonavir Reduces Bupropion Plasma Concentrations in Healthy Subjects

S. Swindells, C. Lindley, G. Yee, 2007, Clinical pharmacology and therapeutics.

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

K. Pradhan, S. Gross, A. Verma, 2016, Cancer research.